Podcast: Recent interventional cardiology trials, ESC 2021

EP 55: 5 Interventional trials that will change your practice: Review of ESC 21 with Dr Mirvat Alasnag

Average (ratings)

No ratings

•

Your rating

In the second ESC 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr. Mirvat Alasnag, interventional Cardiologist and Director of Catheterization Laboratory at the King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Dr Alasnag was a programme committee member at this year’s ESC and regional PI of one of the late-breaking trials presented.

Ankur invites Mirvat to review the interventional cardiology highlights of the congress. Mirvat summarises the background and latest evidence from the trials and their importance. Ankur and Mirvat discuss the strategies they apply currently and how they think the novel data will guide their decision-making.

Trials covered in detail include:

STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome
TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation
RIPCORD 2: does routine pressure wire assessment influence management strategy of coronary angiography for diagnosis of chest pain?
MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest @mirvatalasnag hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

Read MoreRead Less

Episodes

Up Next

Parallax HFSA Edition: Diversity, Equity, Inclusion & Belonging with Dr Nancy M. Albert

EP56 • Oct 11, 2021 • 44m 26s

This week’s Parallax in collaboration with the Heart Failure Society of America (HFSA) explores the many ways organisations can embrace the needs of a diverse community and create a culture that can react to the realities of patientcare.

All Episodes

01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger

EP01 • Apr 23, 2020 • 27m 44s

In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

... 5 6 7 8 9 10 11 12 13

... 11 12 13

21: The “Interventional Intensivist” With Ann Gage

EP21 • Apr 23, 2020 • 32m 18s

We can count on our fingertips how many interventional intensivists exist in the US.

In this episode Ankur Kalra, MD meets with Dr Ann Gage, Cleveland Clinic’s first ‘interventional intensivist’. She discusses her unique skill set, what it means to be an interventionalist in the cath lab but also an expert in cardiovascular intensive care and advocates why such a unique skill set and critical care training are required in today’s modern medicine.

Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.

Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

20: The Staging Of Aortic Valve Disease: A Novel Approach With Joao Cavalcante

EP20 • Apr 23, 2020 • 41m 53s

Dr Cavalcante meets with Ankur Kalra, MD to discuss his recent review published in US Cardiology Review 13.2; on a new aortic stenosis staging system that has important implications for clinical outcomes following aortic valve replacements to aid the treatment of aortic stenosis.

Listen to this, as well as an overview on his interesting childhood and his views on the future of cardiac imaging to treat TAVR.

Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

19: Women In Cardiology With Kendra Grubb

EP19 • Apr 23, 2020 • 41m 30s

The first female cardiac surgeon qualified in the 1960’s. Today there are only 4.5% women in cardiology and only 4% in thoracic surgery. Ankur Kalra meets with Dr Kendra Grubb, the first women to be trained at the University of Virginia, US, on cardiothoracic surgery and the 250th board certified women in thoracic surgery.

Her recent post on social media went viral. It was a photo of an all-women surgical team carrying out a complex structural heart procedure. It had over 100,000 views and was seen by people in over 75 different countries. It’s clear from this online reaction, that now is the time for women to be recognised for the work they are doing in medicine.

Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.

Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

18: The Year 2019 In Review With Sukh Nijjer

EP18 • Apr 23, 2020 • 1h 58m 55s

In our final episode of the year, Ankur has an long conversation with Sukh Nijjer from Imperial College London about the most impactful, exciting and controversial clinical trials of 2019. Sukh and Ankur also discuss how these trials might change practice in the future, and how practice patterns and decisions differ between the US and the UK. In light of an emerging trend of shared decision making between physicians of different specialities and patients with a vast amount of information at their fingertips, Sukh and Ankur examine what tools they use to reconcile the growing data from clinical trials.

Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

17: Rasha Al-Lamee On ORBITA, ISCHEMIA, Coronary Revascularisation & Stable Ischemic Heart Disease

EP17 • Apr 23, 2020 • 38m 2s

Recorded before the American Heart Association (AHA) Scientific Sessions 2019, Ankur is joined by Rasha K Al-Lamee, Interventional Cardiologist at Imperial College Healthcare NHS Trust in London and Study Director of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Rasha talks about how she got into academia, the significance of her end-of-training PhD, and what led to the genesis of ORBITA.

Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

... 19 20 21 22 23 24 ...

... 20 21 22 ...